This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids
by Zacks Equity Research
Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
Top Ranked Income Stocks to Buy for January 23rd
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 23rd:
Alnylam & Medison Partner to Market RNAi Products in Israel
by Zacks Equity Research
Alnylam (ALNY) partners with Israel's Medison Pharma to commercialize Onpattro and other RNAi pipeline candidates under development in the former's portfolio.
Merck's Partner Gets FDA Nod for Herceptin Biosimilar
by Zacks Equity Research
Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.
Top Ranked Income Stocks to Buy for January 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 21st:
Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
by Zacks Equity Research
Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.
Top Ranked Income Stocks to Buy for January 18th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, January 18th
Regeneron (REGN) Sails Steady on Label Expansion of Drugs
by Zacks Equity Research
Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
by Zacks Equity Research
Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Sanofi Wins FDA Nod for Pediatric Hexavalent Combo Vaccine
by Zacks Equity Research
Sanofi (SNY) gains an FDA approval for its pediatric hexavalent combination vaccine, Vaxelis.
The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Microsoft, Mastercard, Sanofi and Dominion Energy
Top Analyst Reports: Apple, Microsoft, Mastercard & More
by Kalyan Nandy
Today's Research Daily features updated research reports on 16 major stocks including Apple Inc. (AAPL), Microsoft Corporation (MSFT) and Mastercard Inc. (MA).
Mylan (MYL) Gets Favorable Ruling Against Sanofi's Lantus
by Zacks Equity Research
Mylan (MYL) gets a favorable ruling from the U.S. PTAB against Sanofi for Lantus.
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
by Kinjel Shah
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
4 Big Pharma Stocks to Add to Your Portfolio in December
by Kinjel Shah
The large-cap pharma industry has been on a strong footing lately. Here are four stocks from the space that investors may consider betting on.
Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs
by Zacks Equity Research
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Novo Nordisk, NVIDIA, Fifth Third Bancorp and Continental Resources
Glaxo Seeks Label Expansion of Nucala in Pediatric Patients
by Zacks Equity Research
Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.
Top Stock Reports for Sanofi, Novo Nordisk & NVIDIA
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Sanofi (SNY), Novo Nordisk (NVO) and NVIDIA (NVDA).
Alphabet Halts Glucose Lens Work to Focus on Other Projects
by Zacks Equity Research
Alphabet's (GOOGL) healthcare unit Verily halts the glucose-measuring contact lens project in order to allocate its resources to other valuable projects.
Regeneron (REGN) Rides on Eylea and Dupixent's Performance
by Zacks Equity Research
Solid performance of approved drugs like Eylea and Dupixent along with an encouraging pipeline progress improve Regeneron's (REGN) market position.
Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges
by Zacks Equity Research
With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
by Zacks Equity Research
Merrimack (MACK) discourages with Q3 loss, falling shy of estimates as well as deteriorates from the year-ago quarter's figure. Also, the company fails to reap any revenues in the period.